Authors

Patrick Hwu, MD

Latest:

Dr. Hwu on the Uptake of Cellular Therapy in Oncology

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Zachery Roger Reichert, MD, PhD

Latest:

Dr Reichert on Key Research Questions in Prostate Cancer

Zachery Roger Reichert, MD, PhD, discusses key research questions to explore in early-stage prostate cancer.

Philip J. Koo, MD

Latest:

Dr Koo on Challenges With PSMA PET in Prostate Cancer

Phillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.

Katelyn Handley, MD

Nikhil Kushalani, MD

Latest:

Current Standard of Care for Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma

Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses current therapeutic options for patients with locally advanced cutaneous squamous cell carcinoma.

Eric S. Christenson, MD

Latest:

Dr Christenson on the Safety of Copanlisib Plus Nivolumab in Pretreated MSS mCRC

Eric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.

Christian Grohé, MD

Latest:

Overview of Frontline Treatment Options in Small Cell Lung Cancer

Moving on to discuss the treatment armamentarium in small cell lung cancer, expert oncologists consider current standards for frontline therapy.

Alessandro Di Federico, MD

Latest:

Dr Di Federico on an Analysis of TTF-1 Expression in Lung Adenocarcinoma

Alessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.

Nagashree Seetharamu, MD, MBBS

Latest:

Dr Seetharamu on Current Platforms Utilized for Molecular Testing in Lung Cancer

Nagashree Seetharamu, MD, MBBS, discusses currently utilized platforms and workflows for molecular testing in lung cancer at Northwell Health.

Krish Patel, MD, Swedish Medical Center

Latest:

Next Steps in Mantle Cell Lymphoma

Talha Badar, MBBS, MD

Latest:

Highlighting Key CML/ALL Data Presented at ASH 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Jay Spiegel, MD

Latest:

Dr Spiegel on the Challenges Associated With CAR T-Cell Therapy in Solid Tumors

Jay Spiegel, MD, discusses some of the challenges of using CAR T-cell therapy in patients with solid tumors.

Melissa B. Davis, PhD

Latest:

Dr. Davis on the Influence of Racial Constructs and Genetic Ancestry in TNBC

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.

David C. Fisher, MD

Latest:

Dr Fisher on Mechanisms of Resistance to Pirtobrutinib in CLL

David C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL

Craig E. Devoe, MD, MS

Latest:

Dr Devoe on Next Steps for Evaluating ELI-002 7P in MRD+ KRAS-Mutant PDAC and CRC

Craig E. Devoe, MD, MS, discusses next steps for assessing the ELI-002 7P vaccine in patients with MRD–positive, KRAS-mutant PDAC and CRC.

Andreas Saltos, MD

Latest:

Dr Saltos on Pembrolizumab Plus Vorinostat in mNSCLC

Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.

Arianna Gianakos, DO

Latest:

Dr Arianna Gianakos: Innovation and Trailblazing Paths in Orthobiologics

Arianna Gianakos, DO, discusses the innovation in orthobiologics and trailblazing paths in equity and advocacy.

Matthew Schwede, MD

Latest:

Building Upon Scaffolds

Cancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.

Moffitt Cancer Center

Latest:

Moffitt Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung Cancer

A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression.

Matthew Manning, MD

Latest:

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.